Loading clinical trials...
Loading clinical trials...
Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease. The ANTARES Study
Conditions
Interventions
Daratumumab
Bortezomib
+2 more
Locations
8
Greece
University of Athens
Athens, Greece
Anticancer Hospital of Thessaloniki
Thessaloniki, Greece
University of Bologna
Bologna, Italy
Univerity of Turin
Torino, Italy
Ankara University
Ankara, Turkey (Türkiye)
Dokuz Eylul University
Balçova, Turkey (Türkiye)
Start Date
October 31, 2019
Primary Completion Date
March 1, 2027
Completion Date
March 1, 2027
Last Updated
April 20, 2026
NCT07249528
NCT06215118
NCT06679101
NCT05969860
NCT06870760
NCT06383143
Lead Sponsor
Stichting European Myeloma Network
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions